(MedPage Today) — ORLANDO — Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily treatment with an oral platelet…
Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118904
Author :
Publish date : 2025-12-09 15:09:00
Copyright for syndicated content belongs to the linked Source.
